Serina Therapeutics Advances Parkinson’s Drug Trial with $21M Financing Boost
Event summary
- Phase 1b registrational study of SER-252 for advanced Parkinson’s disease is underway, with first patient dosed in February 2026.
- Closed $21.2 million private placement financing in March and April 2026 to support SER-252 development.
- First quarter 2026 net loss widened to $6.9 million from $4.8 million in the same period of 2025.
- Cash and cash equivalents totaled $24.5 million as of March 31, 2026, up from $3.1 million at the end of 2025.
- Targeting top-line data from the single-ascending-dose (SAD) study arm of SER-252 in the first half of 2027.
The big picture
Serina Therapeutics is at a critical juncture with its Phase 1b trial of SER-252, a potential breakthrough treatment for advanced Parkinson’s disease. The $21.2 million financing round provides a financial runway, but the company must now deliver on clinical milestones to validate its POZ platform technology. The success of SER-252 could position Serina as a key player in the neurological disease space, leveraging its proprietary drug optimization technology across multiple modalities.
What we're watching
- Clinical Milestones
- Whether SER-252 can demonstrate sufficient safety and efficacy in the Phase 1b trial to support further development.
- Financial Sustainability
- The pace at which Serina can manage its cash burn rate given the increased operating expenses and the need for additional financing.
- Partnership Strategy
- How Serina’s collaboration with Pfizer on the POZ platform will evolve and whether it can attract more strategic partnerships.
Related topics